Labcorp (LH) Stock Forecast & Price Target

Labcorp
Bull Case

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

• Laboratory Co. of America Holdings recently reported strong second-quarter results, beating analyst expectations with earnings per share of $4.99 against a consensus of $4.78, while revenue grew 5.8% year-over-year to $3.73 billion, demonstrating robust operational performance and demand for its diagnostic services.
• The stock is currently trading at $309.85, which is below the consensus price target of $330.00, suggesting potential upside for investors as Wall Street maintains a "Moderate Buy" consensus rating with recent price target increases from firms like Truist Financial and Baird.
• Institutional interest remains strong, with 95.94% of the company's stock owned by institutional investors, and recent filings show new positions being acquired by firms such as Nykredit A S and Baird Financial Group, indicating confidence in the company's long-term stability.
• Laboratory Co. of America Holdings provides a consistent income stream through its dividend, which has a yield of 0.93% and a payout ratio of 23.82%, allowing the company to return cash to shareholders while retaining sufficient capital for growth initiatives and acquisitions.
• The company has reaffirmed its long-term earnings outlook and is actively pursuing acquisitions and investments in laboratory technology following its 2026 Investor Day, signaling a strategic focus on expanding its market share and technological capabilities in the healthcare sector.